Literature DB >> 3005424

Risk factors for cytomegalovirus infection after human marrow transplantation.

J D Meyers, N Flournoy, E D Thomas.   

Abstract

The records of 545 patients were reviewed for risk factors associated with cytomegalovirus (CMV) infection after marrow transplant. CMV infection occurred among 36% of seronegative patients and 69% of seropositive patients. Among seronegative patients, significant risk factors for CMV infection included positive serology of the marrow donor (relative rate, 2.3) and the use of granulocyte transfusions from seropositive donors (relative rate, 2.5). Among both seronegative and seropositive patients, the occurrence of acute graft-versus-host disease (GVHD) significantly increased the risk of CMV infection (average relative rate, 1.8) and of subsequent CMV pneumonia (average relative rate, 2.6). CMV excretion and viremia were each associated with subsequent pneumonia, but the positive predictive values were low. One-third of long-term survivors excreted CMV at greater than 250 days after transplantation. The only risk factor for late excretion was CMV infection that occurred in the first 150 days after transplantation. In contrast to the effect of acute GVHD on CMV infection, CMV infection did not increase the risk of either acute or chronic GVHD.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005424     DOI: 10.1093/infdis/153.3.478

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  118 in total

1.  Human cytomegalovirus transmission from the uterus to the placenta correlates with the presence of pathogenic bacteria and maternal immunity.

Authors:  Lenore Pereira; Ekaterina Maidji; Susan McDonagh; Olga Genbacev; Susan Fisher
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Real-time PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-cell leukemia-lymphoma patients.

Authors:  Junji Ikewaki; Eiichi Ohtsuka; Rie Kawano; Masao Ogata; Hiroshi Kikuchi; Masaru Nasu
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

Review 3.  Prevention of viral infections after bone marrow transplantation.

Authors:  U Schuler; G Ehninger
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

4.  Risk factors for viral reactivation following bone marrow transplantation.

Authors:  D Pillay; A Webster; H G Prentice; P D Griffiths
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

5.  Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116).

Authors:  W J Britt; L G Vugler
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Increase in severity of graft versus host disease by cytomegalovirus.

Authors:  A L McCarthy; J S Malik Peiris; C E Taylor; M A Green; L Sviland; A D Pearson; A J Malcolm
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

7.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

8.  Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice.

Authors:  R H Rubin; P Lynch; M S Pasternack; D Schoenfeld; D N Medearis
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

9.  Evaluation of a latex particle agglutination assay for the detection of cytomegalovirus antibody in patient serum.

Authors:  D A Hursh; A D Abbot; R Sun; J P Iltis; D H Rice; C A Gleaves
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

Review 10.  Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.

Authors:  M F Siadak; K Kopecky; K M Sullivan
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.